Tumor evolution: Linear, branching, neutral or punctuated?

Alexander Davis; Ruli Gao; Nicholas Navin

doi:10.1016/j.bbcan.2017.01.003

Tumor evolution: Linear, branching, neutral or punctuated?

Alexander Davis, Ruli Gao, Nicholas Navin^*

^*Corresponding author for this work

Biochemistry and Molecular Genetics

Research output: Contribution to journal › Article › peer-review

250 Scopus citations

Abstract

Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of how this genetic diversity emerges over time remains limited. A central challenge in studying tumor evolution is the difficulty in collecting longitudinal samples from cancer patients. Consequently, most studies have inferred tumor evolution from single time-point samples, providing very indirect information. These data have led to several competing models of tumor evolution: linear, branching, neutral and punctuated. Each model makes different assumptions regarding the timing of mutations and selection of clones, and therefore has different implications for the diagnosis and therapeutic treatment of cancer patients. Furthermore, emerging evidence suggests that models may change during tumor progression or operate concurrently for different classes of mutations. Finally, we discuss data that supports the theory that most human tumors evolve from a single cell in the normal tissue. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.

Original language	English (US)
Pages (from-to)	151-161
Number of pages	11
Journal	Biochimica et Biophysica Acta - Reviews on Cancer
Volume	1867
Issue number	2
DOIs	https://doi.org/10.1016/j.bbcan.2017.01.003
State	Published - Apr 2017

Funding

This study was supported by a grant from the Lefkofsky Family Foundation. This work is also supported by a grant to N.N. from NCI (1RO1CA169244-01) and from the American Cancer Society (129098-RSG-16-092-01-TBG). N.N. is a T.C. Hsu Endowed Scholar, AAAS Wachtel Scholar and Andrew Sabin Family Fellow. The study is also supported by the Moonshot Knowledge Gap Award. A.D. was supported by a fellowship from the American Legion Auxiliary (ALA) foundation. We thank Alexandria Plumer for reviewing the manuscript.

Keywords

Cancer biology
Cancer genomics
Genome evolution
Intratumor heterogeneity
Single cell genomics
Tumor evolution

ASJC Scopus subject areas

Oncology
Genetics
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbcan.2017.01.003

Cite this

@article{a9b6d894ce6a4c43a28bbbff26a13b2a,

title = "Tumor evolution: Linear, branching, neutral or punctuated?",

abstract = "Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of how this genetic diversity emerges over time remains limited. A central challenge in studying tumor evolution is the difficulty in collecting longitudinal samples from cancer patients. Consequently, most studies have inferred tumor evolution from single time-point samples, providing very indirect information. These data have led to several competing models of tumor evolution: linear, branching, neutral and punctuated. Each model makes different assumptions regarding the timing of mutations and selection of clones, and therefore has different implications for the diagnosis and therapeutic treatment of cancer patients. Furthermore, emerging evidence suggests that models may change during tumor progression or operate concurrently for different classes of mutations. Finally, we discuss data that supports the theory that most human tumors evolve from a single cell in the normal tissue. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.",

keywords = "Cancer biology, Cancer genomics, Genome evolution, Intratumor heterogeneity, Single cell genomics, Tumor evolution",

author = "Alexander Davis and Ruli Gao and Nicholas Navin",

note = "Funding Information: This study was supported by a grant from the Lefkofsky Family Foundation. This work is also supported by a grant to N.N. from NCI (1RO1CA169244-01) and from the American Cancer Society (129098-RSG-16-092-01-TBG). N.N. is a T.C. Hsu Endowed Scholar, AAAS Wachtel Scholar and Andrew Sabin Family Fellow. The study is also supported by the Moonshot Knowledge Gap Award. A.D. was supported by a fellowship from the American Legion Auxiliary (ALA) foundation. We thank Alexandria Plumer for reviewing the manuscript. Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2017",

month = apr,

doi = "10.1016/j.bbcan.2017.01.003",

language = "English (US)",

volume = "1867",

pages = "151--161",

journal = "Biochimica et Biophysica Acta - Reviews on Cancer",

issn = "0304-419X",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Tumor evolution

T2 - Linear, branching, neutral or punctuated?

AU - Davis, Alexander

AU - Gao, Ruli

AU - Navin, Nicholas

N1 - Funding Information: This study was supported by a grant from the Lefkofsky Family Foundation. This work is also supported by a grant to N.N. from NCI (1RO1CA169244-01) and from the American Cancer Society (129098-RSG-16-092-01-TBG). N.N. is a T.C. Hsu Endowed Scholar, AAAS Wachtel Scholar and Andrew Sabin Family Fellow. The study is also supported by the Moonshot Knowledge Gap Award. A.D. was supported by a fellowship from the American Legion Auxiliary (ALA) foundation. We thank Alexandria Plumer for reviewing the manuscript. Publisher Copyright: © 2017 Elsevier B.V.

PY - 2017/4

Y1 - 2017/4

N2 - Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of how this genetic diversity emerges over time remains limited. A central challenge in studying tumor evolution is the difficulty in collecting longitudinal samples from cancer patients. Consequently, most studies have inferred tumor evolution from single time-point samples, providing very indirect information. These data have led to several competing models of tumor evolution: linear, branching, neutral and punctuated. Each model makes different assumptions regarding the timing of mutations and selection of clones, and therefore has different implications for the diagnosis and therapeutic treatment of cancer patients. Furthermore, emerging evidence suggests that models may change during tumor progression or operate concurrently for different classes of mutations. Finally, we discuss data that supports the theory that most human tumors evolve from a single cell in the normal tissue. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.

AB - Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of how this genetic diversity emerges over time remains limited. A central challenge in studying tumor evolution is the difficulty in collecting longitudinal samples from cancer patients. Consequently, most studies have inferred tumor evolution from single time-point samples, providing very indirect information. These data have led to several competing models of tumor evolution: linear, branching, neutral and punctuated. Each model makes different assumptions regarding the timing of mutations and selection of clones, and therefore has different implications for the diagnosis and therapeutic treatment of cancer patients. Furthermore, emerging evidence suggests that models may change during tumor progression or operate concurrently for different classes of mutations. Finally, we discuss data that supports the theory that most human tumors evolve from a single cell in the normal tissue. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.

KW - Cancer biology

KW - Cancer genomics

KW - Genome evolution

KW - Intratumor heterogeneity

KW - Single cell genomics

KW - Tumor evolution

UR - http://www.scopus.com/inward/record.url?scp=85011390859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011390859&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2017.01.003

DO - 10.1016/j.bbcan.2017.01.003

M3 - Article

C2 - 28110020

AN - SCOPUS:85011390859

SN - 0304-419X

VL - 1867

SP - 151

EP - 161

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

IS - 2

ER -

Tumor evolution: Linear, branching, neutral or punctuated?

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this